Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity

Sensitivity of carcinoma cells towards gemcitabine (Gem) has been linked to mitochondrial apoptotic proteins. Recently, we described synergistic efficacy of Gem-based chemoimmunotherapy and a dendritic cell (DC) tumor vaccine in a murine pancreatic carcinoma model. Here, we investigated the role of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of immunotherapy (1997) 2015-04, Vol.38 (3), p.116-126
Hauptverfasser:	Bauer, Christian, Hees, Claudia, Sterzik, Alexander, Bauernfeind, Franz, Mak'Anyengo, Rachel, Duewell, Peter, Lehr, Hans-Anton, Noessner, Elfriede, Wank, Rudolf, Trauzold, Anna, Endres, Stefan, Dauer, Marc, Schnurr, Max
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antigens, Neoplasm - immunology Antimetabolites, Antineoplastic - pharmacology Apoptosis - drug effects Apoptosis - genetics bcl-2-Associated X Protein - genetics bcl-2-Associated X Protein - metabolism Cancer Vaccines Cell Line, Tumor Cytotoxicity, Immunologic - genetics Dendritic Cells - immunology Dendritic Cells - metabolism Deoxycytidine - analogs & derivatives Deoxycytidine - pharmacology Disease Models, Animal Disease Progression Drug Resistance, Neoplasm - genetics fas Receptor - genetics fas Receptor - metabolism Female Gene Expression Gene Silencing Humans Immunotherapy Mice Pancreatic Neoplasms - genetics Pancreatic Neoplasms - immunology Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Pancreatic Neoplasms - therapy Proto-Oncogene Proteins c-bcl-2 - genetics Proto-Oncogene Proteins c-bcl-2 - metabolism RNA Interference T-Lymphocyte Subsets - immunology T-Lymphocyte Subsets - metabolism Tumor Burden - drug effects Tumor Burden - genetics Tumor Burden - immunology Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!